Ireland
--:--IST
Latest
PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch
Clinical Trials in the EU / 2026-525794-39-00
Authorised, not yet recruiting Phase I

A PHASE 1 FIRST-IN-HUMAN OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF ERAS-0015 MONOTHERAPY AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS

2026-525794-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Erasca Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
21/09/2026
Enrollment target
40
Sites
Spain

Condition studied

Solid Tumors

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525794-39-00 on CTIS ↗ ← All trials in the EU